Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alaunos Therapeutics, Inc. (TCRT) SEC filings page on Stock Titan provides direct access to the companys regulatory disclosures, including current reports, registration statements and financing-related documents. These filings show how Alaunos describes its business as combining T-cell receptor (TCR) cell therapy for solid tumors with a preclinical-stage obesity and metabolic health drug development program centered on a small molecule candidate.
Through its Forms 8-K, Alaunos reports material events such as strategic reprioritization steps, capital raises, changes in executive leadership, governance matters and listing status. Recent 8-Ks detail a registered direct offering of common stock and pre-funded warrants under a shelf registration statement on Form S-3, a private offering of Series A-2 Convertible Preferred Stock with dividend, voting and conversion terms, and a settlement and release agreement with The University of Texas M.D. Anderson Cancer Center regarding unpaid invoices under a research and development agreement. Other 8-Ks describe Nasdaq notices of non-compliance and subsequent confirmation that the company regained compliance, as well as stockholder approvals of amendments to increase authorized common stock and adjust capital structure.
Alaunos Form S-1 registration statement outlines its identity as a preclinical-stage obesity and metabolic health drug development company, while also summarizing its history as a clinical-stage oncology-focused cell therapy company and the August 2023 decision to wind down its TCR-T Library Phase 1/2 trial. The S-1 also explains an equity purchase agreement and related warrant that allow the company, at its discretion, to sell common stock to an institutional investor up to a specified aggregate amount.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as financing structures, conversion prices, dividend rights, share authorization changes and listing compliance updates. Users can quickly scan material agreements, capital markets transactions and corporate actions, and then open the full EDGAR documents for detailed review. This page is a central resource for understanding how Alaunos presents its strategy, risks, and capital structure in official SEC documents.
Amendment No. 1 to Schedule 13D reports that PMGC Capital LLC and its parent PMGC Holdings Inc. have completed an exit from their position in Alaunos Therapeutics, Inc. The filing states PMGC LLC sold all of its common stock in open-market transactions between June 16, 2025 and August 22, 2025 at prices ranging from $1.92 to $4.53. Following settlement of the August 22 trades on August 25, 2025, the reporting persons no longer beneficially own any shares of the issuer. The amendment serves as a final amendment and an exit filing; no other new funds, legal proceedings, or retained holdings are reported.
Strategic EP, LLC reported beneficial ownership of 149,827 shares of Alaunos Therapeutics, Inc. common stock, equal to 6.8% of the 2,205,716 shares outstanding as of August 20, 2025. The filing excludes 62,299 shares issuable upon exercise of pre-funded warrants that contain exercise limits tied to ownership thresholds (4.99% or, at holder election, 9.99%). On August 26, 2025, the filer and the issuer entered a Standstill Agreement permitting Strategic EP to exceed the 4.99% limit up to 9.99% and the filer agreed to waive rights to engage in takeover-related activities or otherwise seek to influence control of the company.
Ferdinand Groenewald, identified as Vice President of Finance at Alaunos Therapeutics, Inc. (TCRT), reported transactions dated 08/18/2025. He acquired 10,775 shares of common stock and was granted an employee stock option for 4,000 shares with an exercise price of $2.32 and an expiration date of 08/17/2035. The option vests one-sixteenth of the underlying shares in equal quarterly installments beginning 11/18/2025, subject to continued service.
The Form 4 shows the shares and options are held directly after the transactions. The filing is signed by Mr. Groenewald on 08/20/2025. No additional compensation details or company valuation metrics are provided in this filing.
Holger Weis, Chief Executive Officer and Director of Alaunos Therapeutics, Inc. (TCRT), exercised employee stock options to acquire 13,676 shares on 08/18/2025. The exercised options carry a $2.32 per-share exercise price and are fully vested as of the transaction date, resulting in 13,676 shares beneficially owned by Mr. Weis following the transaction. The Form 4 was signed and dated 08/20/2025 by the reporting person. The filing shows an acquisition via option exercise rather than an open-market purchase and does not report any dispositions or other classes of securities.
Alaunos Therapeutics, Inc. reports that it has regained compliance with the continued listing requirements of the Nasdaq Capital Market. Nasdaq’s Listing Qualifications staff notified the company on August 19, 2025 that the matter is now closed.
The company had previously fallen out of compliance after reporting stockholders’ equity of $2.06 million in its Annual Report for the year ended December 31, 2024, below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1). In its Quarterly Report for the period ended June 30, 2025, Alaunos reported stockholders’ equity of $3.66 million, which met the rule’s threshold and restored compliance.
Form 4 filing for Alaunos Therapeutics, Inc. (TCRT) discloses that director Robert W. Postma received new equity awards on July 3, 2025.
- Restricted stock units (RSUs): 4,050 shares of common stock granted at $0.00 cost and vested immediately, increasing his direct holding to 33,133 shares.
- Stock options: Option to purchase 6,400 shares at an exercise price of $5.00 per share, expiring July 3, 2035. One-twelfth of the option vests monthly starting July 3, 2025; any remaining unvested portion fully vests just before the 2026 annual meeting.
- Indirect holdings: 62,416 shares held through WaterMill Asset Management Corp. and 24 shares in a spouse’s IRA.
The transactions are incentive-based grants rather than market purchases or sales, so they do not immediately affect public float or cash flows. However, they modestly increase insider ownership and further align the director’s interests with shareholders.
Form 4 highlights: Director Jaime Vieser received new equity awards from Alaunos Therapeutics (TCRT) on 07/03/2025.
- Restricted Stock Units (RSUs): 3,400 common shares granted and fully vested immediately. This raised Vieser’s directly held stock from 17,759 to 21,159 shares.
- Employee Stock Options: 6,400 options with a $5.00 exercise price and 07/03/2035 expiry. One-twelfth vests each month; any unvested balance vests immediately before the 2026 annual meeting.
- Total beneficial ownership after the grant: 21,159 shares held directly, 2,100 shares held indirectly through children, and 13,503 shares held indirectly via Brushwood LLC where Vieser is Manager.
The awards were issued at $0.00 cost for the RSUs and standard option pricing for the options, indicating compensation rather than an open-market purchase. While the absolute numbers are modest relative to typical public-company share counts, the filing shows continued equity-based alignment between the director and shareholders.
Alaunos Therapeutics (TCRT) filed a Form 4 disclosing an equity award to recently appointed CEO and director Holger Weis.
- Grant: 130,000 non-qualified stock options with a $5.02 exercise price.
- Vesting: 25 % vests immediately; the remaining 75 % vests in equal quarterly installments over three years starting 2 Oct 2025, contingent on continued employment.
- Expiration: Options are exercisable until 1 Jul 2035.
The award, issued under the company’s 2020 Equity Incentive Plan, increases Weis’s direct derivative holdings to 130,000 options. No common-stock transactions or sales were reported.
FAQ
What is the current stock price of Alaunos Therapeutics (TCRT)?
What is the market cap of Alaunos Therapeutics (TCRT)?
